Palisade Bio wins Canadian clearance for Phase 2 ulcerative colitis trial
AI Summary- Palisade Bio received Health Canada clearance for its ASCENTRA-UC Phase 2 ulcerative colitis study.
- Approximately 204 patients will receive 15-milligram or 30-milligram PALI-2108 doses or placebo.
- Primary efficacy results from the 12-week induction period are expected in the second half of 2027.